BRCA2 and breast carcinoma: Several studies have investigated the oncologic safety of BCT in patients with BRCA pathogenic variants, but the results have varied among these studies.16,17,18,19,20,21,22,23,24 Therefore, current guidelines still specify that patients with breast cancer with genetic predispositions, such as BRCA1 or BRCA2 pathogenic variants, may consider prophylactic bilateral mastectomy for risk reduction.25